Xencor (NASDAQ:XNCR) Trading Up 7.9% – Still a Buy?

Shares of Xencor, Inc. (NASDAQ:XNCR) rose 7.9% during trading on Friday . The company traded as high as $15.97 and last traded at $16.1360. Approximately 127,126 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 796,496 shares. The stock had previously closed at $14.95.

Analyst Ratings Changes

A number of research analysts have weighed in on XNCR shares. Wall Street Zen lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. upped their price target on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Truist Financial cut their price target on Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Six research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $24.25.

Xencor Price Performance

The business’s 50 day simple moving average is $13.21 and its 200 day simple moving average is $12.79. The company has a market capitalization of $1.30 billion, a PE ratio of -7.63 and a beta of 0.86.

Xencor (NASDAQ:XNCR) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The firm had revenue of $4.52 million during the quarter, compared to analyst estimates of $27.86 million. Xencor had a negative net margin of 177.10% and a negative return on equity of 28.77%. The business’s revenue for the quarter was down 86.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.66) earnings per share. As a group, analysts anticipate that Xencor, Inc. will post -3.88 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. ADAR1 Capital Management LLC increased its stake in Xencor by 66.8% during the first quarter. ADAR1 Capital Management LLC now owns 93,665 shares of the biopharmaceutical company’s stock worth $1,130,000 after acquiring an additional 37,500 shares during the last quarter. Quantinno Capital Management LP raised its position in Xencor by 21.1% in the first quarter. Quantinno Capital Management LP now owns 57,077 shares of the biopharmaceutical company’s stock valued at $688,000 after purchasing an additional 9,943 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Xencor by 3.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,294,887 shares of the biopharmaceutical company’s stock valued at $15,613,000 after purchasing an additional 45,599 shares during the last quarter. Principal Financial Group Inc. lifted its stake in shares of Xencor by 2.0% in the 1st quarter. Principal Financial Group Inc. now owns 347,078 shares of the biopharmaceutical company’s stock valued at $4,186,000 after purchasing an additional 6,752 shares during the last quarter. Finally, Fifth Third Bancorp grew its holdings in shares of Xencor by 3,690.2% during the 1st quarter. Fifth Third Bancorp now owns 17,018 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 16,569 shares during the period.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.